Acumen Pharmaceuticals is a biopharmaceutical company that works on treatments for Alzheimer's disease. They focus on developing a drug named ACU193, an immunotherapy candidate that targets soluble amyloid-beta oligomers. Acumen Pharmaceuticals was established in 1996 and has its headquarters based in Virginia.